Recombinant human adenovirus type 5 injection (trade name: Ankrui) is an oncolytic adenovirus anti-tumor drug that contains recombinant adenoviruses that can specifically replicate in tumor cells, cause tumor cell damage, lysis, and further activate immune responses to exert anti-tumor effects. Ankeri was approved for marketing in China in 2005, with an approved indication for advanced nasopharyngeal carcinoma...

On Thursday (June 8th) in the Asian market, Bitcoin's short-term momentum remained volatile and downward, with the currency price dropping to $26338. The US media reported overnight that the List of courts of the United States had approved the freezing of US assets, but it was later changed to "to be confirmed", and the official did not provide further information updates...